Hanmi took a new challenge in patenting the heart failure treatment Entresto (Sacubitril/Valsartan).

It was already challenging other patents and requested an invalidation trial for a more difficult patent. If Hanmi succeeds in overcoming its patent on its own, it is expected that it will be able to release generics earlier than other companies.

According to the pharmaceutical industry on the 3rd, Hanmi filed a trial against Novartis on the last day of last month for invalidation of composition and use patent of Entresto. This patent is known to be the most difficult to overcome among the four patents listed as Entresto.

Patents registered as Entresto are ▲use/composition